GNX1021 is GlycoNex's lead glycan-targeted antibody-drug conjugate (ADC) candidate, developed to treat advanced gastrointestinal cancers including gastric, colorectal, and pancreatic carcinomas. The drug targets branched Lewis B/Y (bLeB/Y), a tumor-associated carbohydrate antigen (TACA) overexpressed on epithelial tumor cells and minimally expressed on healthy human tissue. This selectivity profile underpins the candidate's therapeutic-window potential. In April 2026, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) cleared GNX1021 for first-in-human Phase 1 clinical trials. Taiwan's TFDA has since granted IND approval, enabling a multi-regional Phase 1 across Japan and Taiwan. GNX1021 is built on GlycoNex's proprietary GlycoSH antibody library — one of the most extensive collections of anti-glycan monoclonal antibodies, developed over more than two decades of dedicated glycobiology research at GlycoNex's New Taipei City laboratories.
GNX1021
Glycan-Targeted ADC for Gastrointestinal Cancers
Overview
Mechanism of Action
Antibody recognizes bLeB/Y
Antibody binds branched Lewis B/Y glycan on tumor cell surface
Receptor-mediated internalization
ADC enters cell via endocytosis
Lysosomal cleavage
Linker is cleaved inside lysosome
Payload release
Cytotoxic payload released into cytoplasm
Tumor cell death
Microtubule inhibition triggers mitotic arrest and apoptosis
Most clinical-stage ADCs target protein antigens — HER2, TROP2, Claudin-18.2 — and consequently compete in increasingly crowded indication spaces. GNX1021 instead targets a tumor-associated carbohydrate antigen, exploiting the aberrant glycosylation patterns that distinguish many epithelial cancers from healthy tissue.
Because branched Lewis B/Y is expressed across multiple GI tumor types and is largely independent of HER2 status, GNX1021 has the potential to address HER2-negative patient segments and reach a broader population than any single protein-target ADC.
Indications & Market Opportunity
Gastric Cancer
HER2-negative gastric cancers face limited targeted-therapy options after first-line failure — a clear unmet need for glycan-targeted modalities.
Colorectal Cancer
Refractory mCRC after standard chemotherapy + targeted regimens has 5-year survival under 15%; new ADC targets are urgently needed.
Pancreatic Cancer
Among the deadliest solid tumors, pancreatic adenocarcinoma has minimal viable targeted-therapy options — a classic high-unmet-need ADC opportunity.
bLeB/Y is overexpressed across all three indications, allowing GNX1021 to be developed as a coordinated GI-cancer franchise rather than three siloed programs.
Development Status
-
Discovery & preclinical development
Lead-candidate selection, in vivo efficacy, IND-enabling toxicology and CMC.
-
Preclinical data presented at AACR 2025
Tumor-selective expression and in vivo efficacy disclosed at the American Association for Cancer Research annual meeting.
-
Preclinical data published
Detailed mechanistic and efficacy data released via PR Newswire.
-
Japan PMDA Phase 1 clearance Milestone
PMDA authorizes first-in-human dosing in patients with advanced gastrointestinal cancers.
-
Taiwan TFDA IND clearance Milestone
Taiwan's TFDA grants IND approval, enabling a multi-regional Phase 1 across Japan and Taiwan.
-
Planned
First patient dosing in Japan
Phase 1 site activation at lead investigator hospital; enrollment timing to be confirmed.
-
Phase 1 readout expected
Initial safety, PK, and signal-of-efficacy data.
Why GNX1021 Stands Out
Glycan target advantage
Targets a tumor-associated carbohydrate antigen rather than a protein, broadening tumor coverage and avoiding redundant competition with HER2 / TROP2 / Claudin-18.2 ADCs.
20+ years of glycan antibody science
Drawn from the GlycoSH antibody library, built since GlycoNex's founding in 2001 in collaboration with the late Dr. Sen-itiroh Hakomori (US National Academy of Sciences).
Validated by Japan PMDA
One of the few Taiwan-originated ADCs to clear PMDA review for first-in-human studies, signaling regulatory confidence in the candidate's preclinical package.
Vertically integrated manufacturing
Internal 200L GMP facility supplies clinical material, eliminating CDMO dependency for early-phase supply and protecting timeline integrity.
References
- AACR 2025 Poster — available on request
- PR Newswire — (preclinical data release)
- PR Newswire — (Japan PMDA Phase 1 clearance)
- Taiwan TWSE Material Information Disclosure — TWSE 4168
Partner with us on GNX1021
GlycoNex is actively engaging global pharmaceutical partners on GNX1021 — including out-licensing, regional licensing (ex-Japan), and co-development structures. We welcome discussions with companies whose oncology pipeline aligns with novel glycan-targeted modalities.